Estimation of the prevalence of Fanconi anemia among patients with de novo acute myelogenous leukemia who have poor recovery from chemotherapy

Andrzej Rochowski, Philip S. Rosenberg, Todd A. Alonzo, Robert B. Gerbing, Beverly J. Lange, Blanche P. Alter

Research output: Contribution to journalArticle

Abstract

We speculated that some individuals with de novo acute myelogenous leukemia (AML) may have undiagnosed Fanconi Anemia (FA). Data from patients enrolled on AML protocol CCG-2961, published FA cohort studies, SEER, and Bayes rule were used to estimate the probability of FA among all newly diagnosed AML cases, and among those who had no or delayed recovery of the absolute neutrophil count following initial chemotherapy. We determined that the probability of undiagnosed FA in patients in a treatment trial for newly diagnosed patients was around 0.18%, and around 0.83% in the subset who had poor marrow recovery. We suggest that FA or other inherited bone marrow failure syndromes be considered prior to treatment, or certainly among those with poor recovery.

Original languageEnglish (US)
Pages (from-to)29-31
Number of pages3
JournalLeukemia Research
Volume36
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Keywords

  • Acute myelogenous leukemia
  • Fanconi anemia
  • Prevalence

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Estimation of the prevalence of Fanconi anemia among patients with de novo acute myelogenous leukemia who have poor recovery from chemotherapy'. Together they form a unique fingerprint.

  • Cite this